The present invention relates to novel, non-secosteroidal, phenyl-furan compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1.alpha.,25dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.